



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

February 6, 2018

Corporate Relationship Department
M/s. BSE Ltd
Dalal Street, Fort
Mumbai- 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai -400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclosed herewith the Press Release for your information.

Thanking you

Yours faithfully
For NATCO Pharma Limited

A handwritten signature in black ink that reads "M Adinarayana".

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref:PR/ 15 /2017-2018

Press Release

Hyderabad, 6th February, 2018

NATCO records INR 573.6 Crore revenue and INR 217.4 Crore of Profit, after tax, for the Third Quarter, FY 2017-18

Hyderabad based NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has recorded consolidated total revenues of INR 573.6 Crore for the quarter ended on 31st December, 2017, as against INR 685.1 Crore during the same quarter last year. The decline in revenue compared to last year's quarter was predominantly due to large stocking quantities of generic oseltamivir during last year's period.

The company is very pleased to show strong earnings during the quarter, in spite of loss of exclusivity for generic oseltamivir in the USA market. We successfully launched several new products in the USA market recently, that includes generic versions of glatiramer acetate, oseltamivir suspension, liposomal doxorubicin and lanthanum carbonate, and continue to believe in strong growth in ensuing quarters. The net profit for the period, on a consolidated basis, was INR 217.4 Crore, as against INR 194.9 Crore same quarter last year, showing a growth of 11.5%.

Forwarded for favour of publication
For NATCO Pharma Limited

M Adinarayana

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)